Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial

Citation
Hd. Bear et al., Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial, CANCER IMMU, 50(5), 2001, pp. 269-274
Citations number
37
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
CANCER IMMUNOLOGY IMMUNOTHERAPY
ISSN journal
0340-7004 → ACNP
Volume
50
Issue
5
Year of publication
2001
Pages
269 - 274
Database
ISI
SICI code
0340-7004(200107)50:5<269:AIOCWP>2.0.ZU;2-H
Abstract
Adoptive immunotherapy (AIT) of cancer with T lymphocytes may be limited by the need to activate tumor antigen-sensitized cells in vitro. In murine mo dels, we have shown that AIT with tumor-sensitized T cells that have been p harmacologically activated with bryostatin I and ionomycin plus interleukin -2 can induce tumor regression. A Phase I clinical trial was carried out to assess the feasibility and toxicity associated with using tumor- or vaccin e-draining lymph node cells, activated pharmacologically and expanded in cu lture with low-dose interleukin-2 and infused intravenously, followed by IL -2 infusion. Nine patients were entered into the trial, and six were treate d as planned. Average expansion of cell numbers over 13 to 27 days in cultu re was 118-fold. No patient's cells reached the target cell number (2.5 x 1 0(10)). Infusion of these cells did not result in any unexpected toxicities . The toxicities observed were related to IL-2 infusion, and conformed to t he expected range of side-effects. Based on these Phase I results, addition al trials, with tumor antigen vaccine-sensitized DLN and technical modifica tions of the culture technique, are planned.